Old name, new purpose: why we’ve gone back to RNID

Market intelligence

We provide expert advice to pharmaceutical, biotechnology and medical-device companies on the current status of, and opportunities in, the hearing loss and tinnitus therapy areas.

Our advice covers:

  • current status of hearing loss and tinnitus R&D – small molecule, cell-based and biologic approaches; drugs in development to treat hearing loss and tinnitus
  • subtypes of acquired hearing loss: age-related hearing loss, noise-induced hearing loss, ototoxicity
  • subtypes of genetic hearing loss
  • insight into targets and mechanistic pathways of therapeutic interest
  • market size.

Treatments for inner ear disorders and tinnitus in development

The Hearing Therapeutics Initiative recently published an analysis of potential new treatments currently at different stages of development: Isherwood B et al (2022) The global hearing therapeutic pipeline 2021, Drug Discovery Today 27(3).

Please contact hti@rnid.org.uk to request a copy of the paper.

We maintain an overview of companies working in the field of therapeutics for inner ear and central hearing disorders, their therapeutics approaches, indications, products, mechanisms of action and phases of development. This information is summarized in the table below and updated regularly:

Download the 2021 hearing therapeutic pipeline data

To find out more, please email hti@rnid.org.uk